The CGRP Monoclonal Antibodies: Revolutionary Breakthrough or Over-priced Hype?

The CGRP Monoclonal Antibodies: Revolutionary Breakthrough or Over-priced Hype?

In May of last year, the US Food and Drug Administration (FDA) approved erenumab (Aimovig), the first of the anti-calcitonin gene related peptide (CGRP) therapies for the indication of migraine prevention.  Aimovig quickly became available for general clinical use and already has been prescribed for well over 100,000 patients with episodic or chronic migraine. Within a period of months 2 more received similar FDA approval and entered the market: galcanezumab (Emgality) and fremanezumab (Ajovy).  

Read More